- Home » News and Events

NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Announces New Operating Structure
Jul 5, 2022
Catalent’s new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shiga, Japan
Jun 29, 2022
Catalent today announced that it has expanded its primary packaging capabilities at its clinical supply facility in Shiga, Japan, through the installation of a high-speed blister packaging line to complement its existing automated bottling line.
Catalent Experts to Discuss Managing Successful Direct-to-Patient Clinical Supplies and Overcoming Product Launch Challenges at Upcoming BSMA Conference
Jun 16, 2022
Catalent today announced that company experts will be speaking on current clinical market trends and strategies at two upcoming conferences: Clinical Trial Supply New England; and Clinical Trial Supply Europe.
Catalent Supports U.S. Launch of Phathom Pharmaceuticals’ New Products Following Regulatory Approval
Jun 9, 2022
Catalent today welcomed the recent announcement by Phathom Pharmaceuticals that the U.S. Food and Drug Administration has approved both VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA™ DUAL PAK™ for the treatment of Helicobacter pylori infection in adults.
Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Jun 7, 2022
Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet technology for delivering the MigVax-101 vaccine.
Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winchester, Kentucky
May 19, 2022
Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.
Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
May 16, 2022
The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.
Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility
Apr 28, 2022
Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.
Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech
Apr 25, 2022
Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.
Integrated Clinical Development and Supply: Breaking Down the Early-Development Journey of a Small Molecule
Date: August 31, 2022
Advanced Therapies Europe 2022
Date: August 31 – September 1, 2022
New Updates In Drug Formulation and Bioavailability
Date: September 6, 2022
World ADC San Diego 2022
Date: September 6-9, 2022
Connect In Pharma 2022
Date: September 14-15, 2022
CAR TCR Summit US 2022
Date: September 19-22, 2022
12th American Drug Delivery & Formulation Summit
Date: September 26-27, 2022
BPI East 2022
Date: September 27-30, 2022
BioForward 2022
Date: September 27, 2022
Nordic Life Science Days 2022
Date: September 28-29, 2022
Inhalation & Respiratory Drug Delivery USA Congress
Date: October 11-12, 2022
AAPS 2022 PharmSci 360
Date: October 16-19, 2022
SupplySide West 2022
Date: October 31- November 4, 2022